

# Sustained Sirolimus Release DEB for CLI Treatment

Michael K. W. Lichtenberg MD, FESC



# Conflict of Interest - Disclosure

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

## Affiliation/Financial Relationship

## Company

1. Honoraria for lectures: CR Bard, Boston Scientific AB Medica, Volcano, Optimed GmbH, Straub Medical, Terumo, Biotronik, Veryan, Intact Vascular, Vesper
2. Honoraria for advisory board activities: Veniti, Optimed GmbH, Straub Medical, Biotronik, Veryan, Boston Scientific, Philips, Intact Vascular, Vesper
3. Participation in clinical trials: Biotronik, CR Bard, Veryan, Straub Medical, Veniti, Boston Scientific, LimFlow, Terumo, Philips, Optimed, IP Medical, Abbott, Vesper, Vetex,
4. Research funding: Biotronik, Boston Scientific, Veryan, Veniti, AB Medica, Philips, CR Bard, Optimed, Intact Vascular, Abbott.

# Case presentation

- 78 y male patient
- Rutherford V
  - left D1 and DII dry necrosis
- CVRF: Smoking, CKD, Diabetes (HbA1c 8.1%)
- Post CABG (2016)
- Ipsilateral ATA intervention 7 months before with POBA

# Sirolimus DCB angioplasty below the knee

Dr. Michael Lichtenberg  
Vascular Center Arnsberg, Germany

ATTRIBUTE	SIROLIMUS (OR ANALOGS)	PACLITAXEL (PTX)
MODE OF ACTION	CYTOSTATIC	CYTOTOXIC
MARGIN OF SAFETY	10'000 FOLD	100 FOLD
THERAPEUTIC RANGE	WIDE	NARROW
ANTI-RESTENOTIC	YES Lower Late Lumen Loss	YES
ANTI-INFLAMMATORY	YES	NO
TISSUE ABSORPTION	SLOW	FAST
TISSUE RETENTION	SHORT	LONG